Tag - ACTU

Developments

Nature Medicine publishes Actuate’s data from trial of elraglusib + chemo in mPC

Actuate Therapeutics (NASDAQ: ACTU) has announced the publication of new data in Nature Medicine from its Phase 2 clinical trial evaluating elraglusib in combination with the gemcitabine-Nab-paclitaxel (GnP)...

April 14, 2026

Developments

Actuate to advance Elraglusib tablet to Phase 1/2 program in refractory cancers

Actuate Therapeutics (NASDAQ: ACTU) has announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patients with advanced cancer. According to Actuate, the goal of...

January 21, 2026

Developments

Actuate announces positive Phase 1 elraglusib results in pediatric cancer

Actuate Therapeutics (NASDAQ: ACTU) has announced results from the phase 1 portion of its Actuate-1902 Phase 1/2 clinical study evaluating elraglusib as a monotherapy or in combination with irinotecan, irinotecan plus...

January 7, 2026

Tag - ACTU

Nature Medicine publishes Actuate’s data from trial of elraglusib + chemo in mPC

Actuate to advance Elraglusib tablet to Phase 1/2 program in refractory cancers

Actuate announces positive Phase 1 elraglusib results in pediatric cancer

Subscribe